Ignite Creation Date:
2025-12-25 @ 3:37 AM
Ignite Modification Date:
2026-02-26 @ 7:49 PM
Study NCT ID:
NCT05328102
Status:
TERMINATED
Last Update Posted:
2024-04-30
First Post:
2022-04-04
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)
Sponsor:
Xencor, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-04-15
Start Date Type:
ACTUAL
Primary Completion Date:
2023-02-21
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-02-21
Completion Date Type:
ACTUAL
First Submit Date:
2022-04-04
First Submit QC Date:
None
Study First Post Date:
2022-04-14
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2024-02-19
Results First Submit QC Date:
None
Results First Post Date:
2024-04-30
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-04-04
Last Update Post Date:
2024-04-30
Last Update Post Date Type:
ACTUAL